HISTORICAL FACTS: Are wall street analysts bullish on biogen stock - The Untold Story

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies in the United States and internationally. The company has a market cap of $28.1 billion and focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, and others.

BIIB shares have rallied the broader market over the past year, surged 47.2% compared to the S&P 500 Index ($SPX) 23.3% surge. Moreover, in 2026, the stock has grown nearly 8.3%, outperforming the SPX’s 7.4% rise as well.